Magnetic resonance imaging of the liver: Consensus statement from the 1st International Primovist User Meeting

Dermot Malone, Christoph Johannes Zech, Carmen Ayuso, Carlo Bartolozzi, Eduard Jonas, Akihiro Tanimoto

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The role of contrastenhanced liver MRI using the hepatocyte-specific agent gadoliniumethoxybenzyl-diethylene triamine penta-acetic acid (Gd-EOB-DTPA, Primovist, Bayer Schering Pharma, Berlin, Germany) is considered, based on the discussion at the Forum of Liver MRI: The 1st International Primovist User Meeting. Current clinical evidence supports Gd-EOB-DTPA's use in non-invasive diagnosis of benign and malignant liver lesions and staging of focal and diffuse liver disease. The information thus gained assists in the provision of cost-effective patient management. The pharmacological properties of Gd-EOB-DTPA facilitate the imaging of both the vascular and hepatobiliary phases in the cirrhotic and non-cirrhotic liver and may provide an opportunity for one-stop diagnosis of liver lesions, such as focal nodular hyperplasia, adenomas, haemangiomas, hepatocellular carcinoma and metastases. The currently recommended protocols using Gd-EOB-DTPA are appropriate for the majority of patients, but imaging time points may require modification in specific patient groups. Further experience in routine clinical practice, as opposed to that gained from rigidly designed clinical studies, may provide greater understanding of the potential of Gd-EOB-DTPA for the evaluation of the cirrhotic and non-cirrhotic liver. Additional studies may substantiate the potential of Gd-EOB-DTPA in the imaging of other abdominal organs and in the evaluation of liver function and fibrosis.

Original languageEnglish
Pages (from-to)849-864
Number of pages16
JournalEuropean Radiology, Supplement
Volume18
Issue numberSUPPL. 4
DOIs
Publication statusPublished - 2008

Fingerprint

Magnetic Resonance Imaging
Liver
Focal Nodular Hyperplasia
Rubiaceae
gadolinium ethoxybenzyl DTPA
Berlin
Hemangioma
Acetic Acid
Liver Cirrhosis
Adenoma
Germany
Blood Vessels
Liver Diseases
Hepatocytes
Hepatocellular Carcinoma
Pharmacology
Neoplasm Metastasis
Costs and Cost Analysis

Keywords

  • Contrast-enhanced
  • Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid
  • Liver lesions
  • Magnetic resonance imaging

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Magnetic resonance imaging of the liver : Consensus statement from the 1st International Primovist User Meeting. / Malone, Dermot; Zech, Christoph Johannes; Ayuso, Carmen; Bartolozzi, Carlo; Jonas, Eduard; Tanimoto, Akihiro.

In: European Radiology, Supplement, Vol. 18, No. SUPPL. 4, 2008, p. 849-864.

Research output: Contribution to journalArticle

Malone, Dermot ; Zech, Christoph Johannes ; Ayuso, Carmen ; Bartolozzi, Carlo ; Jonas, Eduard ; Tanimoto, Akihiro. / Magnetic resonance imaging of the liver : Consensus statement from the 1st International Primovist User Meeting. In: European Radiology, Supplement. 2008 ; Vol. 18, No. SUPPL. 4. pp. 849-864.
@article{3571a29a8cf344c7be2ab849f1e3a391,
title = "Magnetic resonance imaging of the liver: Consensus statement from the 1st International Primovist User Meeting",
abstract = "The role of contrastenhanced liver MRI using the hepatocyte-specific agent gadoliniumethoxybenzyl-diethylene triamine penta-acetic acid (Gd-EOB-DTPA, Primovist, Bayer Schering Pharma, Berlin, Germany) is considered, based on the discussion at the Forum of Liver MRI: The 1st International Primovist User Meeting. Current clinical evidence supports Gd-EOB-DTPA's use in non-invasive diagnosis of benign and malignant liver lesions and staging of focal and diffuse liver disease. The information thus gained assists in the provision of cost-effective patient management. The pharmacological properties of Gd-EOB-DTPA facilitate the imaging of both the vascular and hepatobiliary phases in the cirrhotic and non-cirrhotic liver and may provide an opportunity for one-stop diagnosis of liver lesions, such as focal nodular hyperplasia, adenomas, haemangiomas, hepatocellular carcinoma and metastases. The currently recommended protocols using Gd-EOB-DTPA are appropriate for the majority of patients, but imaging time points may require modification in specific patient groups. Further experience in routine clinical practice, as opposed to that gained from rigidly designed clinical studies, may provide greater understanding of the potential of Gd-EOB-DTPA for the evaluation of the cirrhotic and non-cirrhotic liver. Additional studies may substantiate the potential of Gd-EOB-DTPA in the imaging of other abdominal organs and in the evaluation of liver function and fibrosis.",
keywords = "Contrast-enhanced, Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid, Liver lesions, Magnetic resonance imaging",
author = "Dermot Malone and Zech, {Christoph Johannes} and Carmen Ayuso and Carlo Bartolozzi and Eduard Jonas and Akihiro Tanimoto",
year = "2008",
doi = "10.1007/s10406-008-0010-1",
language = "English",
volume = "18",
pages = "849--864",
journal = "European Radiology, Supplement",
issn = "1613-3749",
publisher = "Springer Verlag",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Magnetic resonance imaging of the liver

T2 - Consensus statement from the 1st International Primovist User Meeting

AU - Malone, Dermot

AU - Zech, Christoph Johannes

AU - Ayuso, Carmen

AU - Bartolozzi, Carlo

AU - Jonas, Eduard

AU - Tanimoto, Akihiro

PY - 2008

Y1 - 2008

N2 - The role of contrastenhanced liver MRI using the hepatocyte-specific agent gadoliniumethoxybenzyl-diethylene triamine penta-acetic acid (Gd-EOB-DTPA, Primovist, Bayer Schering Pharma, Berlin, Germany) is considered, based on the discussion at the Forum of Liver MRI: The 1st International Primovist User Meeting. Current clinical evidence supports Gd-EOB-DTPA's use in non-invasive diagnosis of benign and malignant liver lesions and staging of focal and diffuse liver disease. The information thus gained assists in the provision of cost-effective patient management. The pharmacological properties of Gd-EOB-DTPA facilitate the imaging of both the vascular and hepatobiliary phases in the cirrhotic and non-cirrhotic liver and may provide an opportunity for one-stop diagnosis of liver lesions, such as focal nodular hyperplasia, adenomas, haemangiomas, hepatocellular carcinoma and metastases. The currently recommended protocols using Gd-EOB-DTPA are appropriate for the majority of patients, but imaging time points may require modification in specific patient groups. Further experience in routine clinical practice, as opposed to that gained from rigidly designed clinical studies, may provide greater understanding of the potential of Gd-EOB-DTPA for the evaluation of the cirrhotic and non-cirrhotic liver. Additional studies may substantiate the potential of Gd-EOB-DTPA in the imaging of other abdominal organs and in the evaluation of liver function and fibrosis.

AB - The role of contrastenhanced liver MRI using the hepatocyte-specific agent gadoliniumethoxybenzyl-diethylene triamine penta-acetic acid (Gd-EOB-DTPA, Primovist, Bayer Schering Pharma, Berlin, Germany) is considered, based on the discussion at the Forum of Liver MRI: The 1st International Primovist User Meeting. Current clinical evidence supports Gd-EOB-DTPA's use in non-invasive diagnosis of benign and malignant liver lesions and staging of focal and diffuse liver disease. The information thus gained assists in the provision of cost-effective patient management. The pharmacological properties of Gd-EOB-DTPA facilitate the imaging of both the vascular and hepatobiliary phases in the cirrhotic and non-cirrhotic liver and may provide an opportunity for one-stop diagnosis of liver lesions, such as focal nodular hyperplasia, adenomas, haemangiomas, hepatocellular carcinoma and metastases. The currently recommended protocols using Gd-EOB-DTPA are appropriate for the majority of patients, but imaging time points may require modification in specific patient groups. Further experience in routine clinical practice, as opposed to that gained from rigidly designed clinical studies, may provide greater understanding of the potential of Gd-EOB-DTPA for the evaluation of the cirrhotic and non-cirrhotic liver. Additional studies may substantiate the potential of Gd-EOB-DTPA in the imaging of other abdominal organs and in the evaluation of liver function and fibrosis.

KW - Contrast-enhanced

KW - Gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid

KW - Liver lesions

KW - Magnetic resonance imaging

UR - http://www.scopus.com/inward/record.url?scp=56749103194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=56749103194&partnerID=8YFLogxK

U2 - 10.1007/s10406-008-0010-1

DO - 10.1007/s10406-008-0010-1

M3 - Article

AN - SCOPUS:56749103194

VL - 18

SP - 849

EP - 864

JO - European Radiology, Supplement

JF - European Radiology, Supplement

SN - 1613-3749

IS - SUPPL. 4

ER -